NCT05900141View on ClinicalTrials.gov

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

August 24, 2028

Study Completion Date

August 24, 2028

Conditions
Hyperlipoproteinemia (a)
Interventions
DRUG

Pelacarsen

Pelacarsen 80mg s.c. monthly

Trial Locations (9)

13353

Novartis Investigative Site, Berlin

49661

Novartis Investigative Site, Cloppenburg

55131

Novartis Investigative Site, Mainz

60431

Novartis Investigative Site, Frankfurt am Main

81377

Novartis Investigative Site, München

89081

Novartis Investigative Site, Ulm

91054

Novartis Investigative Site, Erlangen

97080

Novartis Investigative Site, Würzburg

01307

Novartis Investigative Site, Dresden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY